synthetic phylomer libraries, page-2

Hi Tony,
Synthetic phylomers are a new addition to my research. Yet, here we are dealing with an investment bank which specializes in providing strategic advisory services to companies with change-the-world synthetic biology technology (and healthcare-life sciences).

I particularly enjoy the fact that synthetic phylomer libraries facilitate phenotypic screening which has become the topic du jour.

I didn't know what to make of the announcement at first. I re-played last weeks presentation by the CFO at the Sydney Investor Evening. Woolf would have prepared his speech to investors fully cognisant of the pending engagement of Griffin Securities. Its interesting to note the following remark from the evening presentation;

"We think we're going to get acquired and we are moving towards that path."

I personally view today's announcement as a concrete movement along the path to a trade sale. It doesn't at all mean, however, that a trade sale is imminent. Stecyk, the CEO of Griffin discusses the importance of building shareholder value through broad therapeutic discovery alliances, partnerships within industry, agriculture and animal husbandry as well as collaborations with companies with synergistic technology. Merger and acquisition with companies with synergistic technology can't be discounted.

Reducing risk, adding value, providing validated leads and championing your hits are key concepts for deal making with Big Pharma. Special thanks to BioExec for the insights.

Regards,

Wayne.